VXRT News and Press, Vaxart Inc. From 11/16/21

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vaxart’s COVID-19 oral vaccine candidate...

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be participating in virtual fireside chat...

Vaxart (NASDAQ:VXRT): Q3 GAAP EPS of -$0.14 in-line. Revenue of $0.2M (-25.9% Y/Y) beats by $0.08M. Press Release For further details see: Vaxart EPS in-line, beats on revenue

Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to support rapid clinical advancement of pipeline programs Ended the quarter with $204 million in cash, cash equivalents...

Cantor Fitzgerald has initiated the coverage of Vaxart (VXRT +0.8%) with an Overweight recommendation noting the prospects of the company’s vaccine candidates for norovirus and SARS-CoV-2. The company focused on orally-administered vaccines has potential to take programs toward market ...

On Oct 26, Vaxart announced dosing of the first subject in their Phase 2 COVID-19 oral tablet vaccine trial. The company has also updated their corporate presentation recently. I take a close look at Vaxart's COVID-19 program and share my thoughts. For further details see: ...

Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial Study Will Evaluate Safety, Immunogenicity and Efficacy of the Only Oral Tablet COVID-19 Vaccine in Phase II Vaxart Now Operates Two Manufacturing Facilities To Support Timely Progress of Mult...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Up until now, I’ve been bullish on Covid-19 vaccine play Novavax (NASDAQ: NVAX ). I felt its international order backlog made up for its lack of progress in entering the U.S. market. This pointed to further ups...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips First off, it makes sense why many may be skeptical about Vaxart  (NASDAQ: VXRT ). One of the lesser-known Covid-19 vaccine companies, VXRT stock has seen a big drop in popularity from its peaks in 2020. Given how...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Covid-19 cases are decreasing across the U.S. and parts of Europe, but for the nations still struggling to gain access to vaccines, a recent setback in production means further bad news. Maryland-based Novavax (NASDAQ: ...